Phosphate therapy's hidden toll on aging bodies revealed
NCT ID NCT03771105
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how long-term phosphate therapy affects the kidneys, blood vessels, and heart in people with two rare bone disorders: X-linked hypophosphatemia (XLH) and hereditary hypophosphatemic rickets with hypercalciuria (HHRH). Researchers will measure hormone levels and check organ function in 30 participants aged 13 and older. The goal is to understand the risks of current treatments and how they might influence healthy aging.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HHRH are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yale University School of Medicine
RECRUITINGNew Haven, Connecticut, 06511, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Dental scans and AI could spot rare bone diseases faster
- Common antibiotic could tame rare calcium disorder
- Old heart drug may help kidney transplant patients with low phosphate
- New diaper-like device could spare preemies from painful urine tests
- ICU phosphate study: less may be more
- New phosphate granules aim to fix dangerous mineral deficiency in hospital patients